Ruvie Martin
- Rheumatology top 0.5%
- Spondyloarthritis Studies and Treatments 14
- Rheumatoid Arthritis Research and Therapies 10
- Systemic Lupus Erythematosus Research 4
- Hematology top 2%
- Autoimmune and Inflammatory Disorders Research 11
- Immunology top 2%
- Psoriasis: Treatment and Pathogenesis 11
- Neurology top 5%
- Cerebrovascular and genetic disorders 3
- Dermatology top 5%
- Hidradenitis Suppurativa and Treatments 4
-
- Colorectal and Anal Carcinomas 3
- Co-authors
- Hanno B. RichardsShephard MpofuBrian PorterDominique BaetenXenofon BaraliakosJoachim SieperJürgen BraunPaul Emery
- Cited by
- RheumatologyHematologyImmunology
- Partner nations
- SwitzerlandUnited StatesUnited Kingdom
In The Last Decade
Ruvie Martin
27 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 89
- Rheumatology 1.3k
- Hematology 579
- Immunology 1.0k
- Neurology 335
- Dermatology 129
Countries citing papers authored by Ruvie Martin
This map shows the geographic impact of Ruvie Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruvie Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruvie Martin more than expected).
Fields of papers citing papers by Ruvie Martin
This network shows the impact of papers produced by Ruvie Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruvie Martin. The network helps show where Ruvie Martin may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ruvie Martin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 5 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 6 | |
| 8 | 2022 | 2 | |
| 9 | 2020 | 3 | |
| 10 | 2020 | 179 | |
| 11 | 2020 | 33 | |
| 12 | 2020 | 19 | |
| 13 | 2018 | 24 | |
| 14 | 2018 | 83 | |
| 15 | 2016 | 188 | |
| 16 | 2016 | 64 | |
| 17 | Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitisbreakdown → | 2015 | 732 |
| 18 | 2004 | 312 | |
| 19 | 2003 | 66 | |
| 20 | 1993 | 3 |
About Ruvie Martin
Ruvie Martin is a scholar working on Rheumatology, Hematology and Immunology, having authored 29 papers that have together received 2.1k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (14 papers), Psoriasis: Treatment and Pathogenesis (11 papers), Autoimmune and Inflammatory Disorders Research (11 papers), Rheumatoid Arthritis Research and Therapies (10 papers), Systemic Lupus Erythematosus Research (4 papers), Hidradenitis Suppurativa and Treatments (4 papers), Colorectal and Anal Carcinomas (3 papers) and Cerebrovascular and genetic disorders (3 papers). The work is most often cited by research in Rheumatology (1.3k citations), Hematology (579 citations) and Immunology (1.0k citations). Ruvie Martin has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include Hanno B. Richards, Shephard Mpofu, Brian Porter, Dominique Baeten, Xenofon Baraliakos, Joachim Sieper, Jürgen Braun, Paul Emery, Atul Deodhar and Maxime Dougados. Their work appears in journals such as New England Journal of Medicine, The Lancet and Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.